psychedelic-assisted psychotherapy

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential

mycolabadmin

Psychedelic drugs like LSD and psilocybin are substances that alter perception and consciousness. Research shows they may help treat serious mental health conditions including depression, anxiety, and PTSD by affecting how the brain forms new connections. These substances are relatively safe compared to many legal drugs, and scientists believe they could revolutionize mental health treatment when used properly under medical supervision.

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Reporting of psychotherapeutic methods in psychedelic treatments: on the road to ethical, professional and regulatory oversight

mycolabadmin

Researchers reviewed 45 studies on how psychedelic drugs like psilocybin, MDMA, and LSD are used to treat mental health conditions. They found that scientists were not describing the psychological counseling that accompanies these treatments in a consistent or detailed way, making it hard to understand how treatments really work. The study calls for better documentation standards so that treatments can be properly regulated, replicated, and made safer for patients.

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials

mycolabadmin

This systematic review examines how psychedelic-assisted therapies like ketamine and psilocybin help people with severe, treatment-resistant depression that doesn’t respond to standard antidepressants. The analysis of 10 recent clinical trials shows these therapies work quickly, often providing symptom relief within days rather than weeks, and importantly, they also help people return to work and daily functioning. These treatments are generally well-tolerated with minimal cognitive side effects, suggesting they could become important new options for patients who haven’t benefited from conventional depression treatments.

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

mycolabadmin

Researchers are rediscovering psychedelic compounds from traditional plants and fungi as potential treatments for mental health conditions and addiction. These substances work by interacting with brain chemistry, particularly serotonin systems, to reduce symptoms of depression, anxiety, and drug cravings. Recent clinical studies show promising results, especially for treating opioid addiction with single doses that can produce lasting improvements. However, more rigorous clinical trials are needed to fully understand how these compounds work and to establish safe, effective therapeutic protocols.

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress

mycolabadmin

A study asked 31 palliative care patients about their views on using psilocybin (a compound from magic mushrooms) as a treatment for existential distress—the emotional and spiritual suffering that comes with terminal illness. Over half the patients were interested in trying this therapy, especially if they believed it could help with anxiety and stress. However, patients were concerned about risks like psychosis, the lack of trained therapists, and the potential for doctors to take advantage of them during treatment. The researchers concluded that while psilocybin-assisted therapy shows promise, there needs to be better education and strict safeguards to protect vulnerable patients.

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

mycolabadmin

Two patients with severe anorexia nervosa received psilocybin-assisted therapy and unexpectedly recovered memories of sexual assault that had been unconsciously suppressed. Processing these traumatic memories with professional support led both patients to achieve remission from their eating disorders within three months. This case report suggests that psilocybin may help unlock and heal deeply buried trauma underlying eating disorders, though more research is needed to understand how this works and ensure patient safety.

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

mycolabadmin

This study tests whether psilocybin (the active compound in certain mushrooms) can help people with obsessive-compulsive disorder who haven’t responded to standard treatments. In a carefully controlled trial, participants receive either a single dose of psilocybin or a placebo while receiving psychological support, with their brain activity and symptoms monitored. The research aims to determine if this novel treatment is safe and whether it could work faster than existing medications for this difficult-to-treat condition.

Psychedelic-assisted therapy – supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics

mycolabadmin

This paper critically examines recent clinical trials testing MDMA and psilocybin for treating PTSD and depression. While these trials reported promising results, the author identifies serious scientific and ethical problems: participants could tell whether they received the drug or placebo due to its strong effects, researchers and therapists who strongly believed in the treatment may have unconsciously influenced patient responses, and negative side effects may have been downplayed. The author argues that without fixing these problems, the entire field of psychedelic therapy research could lose credibility.

Research Topic: psychedelic-assisted psychotherapy